Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Mayo Clinic CEO Offers New Vision for Personalized Patient Care

March 4, 2009

WASHINGTON, March 4 /PRNewswire/ — Denis A. Cortese, M.D., president and
CEO of the Mayo Clinic, offered a new vision for personalized healthcare in
America at a time when Congress and the administration are discussing changes
in the healthcare system.

The Mayo Clinic is committed to implementing personalized medicine for its
patients. By targeting specific treatments to individual patients based on an
analysis of differences in their molecular makeup, personalized medicine
increases the effectiveness and safety of many existing therapies and spurs
the creation of new treatments.

Dr. Cortese was introduced by Paul Stoffels, M.D., company group chairman,
global pharmaceutical research and development, Johnson & Johnson. Dr.
Stoffels said that Johnson & Johnson is committed to a personalized approach
to medicine, using its broad expertise in healthcare research and development
to develop targeted therapies for major diseases.

The keynote address at the Personalized Medicine Coalition’s annual
luncheon took place against the backdrop of the Obama Administration’s health
reform summit, which the president announced last week in his address to
Congress. Johnson & Johnson sponsored the luncheon, which was held at the
National Press Club.

Dr. Cortese discussed how Mayo Clinic’s implementation of personalized
medicine works in practice and what it means for Mayo’s patients. He
emphasized the importance of interoperable computerized patient records and
communication among different providers in determining the optimal treatments
for individual patients.

“Health information technology plays a huge role in synthesizing large
amounts of data, creating knowledge that will drive evidence-based decision
making,” Dr. Cortese said.

These insights should guide spending for two sums in the economic stimulus
package: $19.2 billion for health information technology, and $1.2 billion to
compare the effectiveness of different treatments for diseases.

Dr. Stoffels described Johnson & Johnson’s commitment to incorporating
pharmacogenomics and biomarkers during the drug development process, which
allows scientists and researchers to improve outcomes of successful drug
candidates while better meeting patient needs. He emphasized that
collaboration among industry, academia, providers, and payers has the power to
fuel even faster development and implementation of personalized medicine
solutions.

“At Johnson & Johnson, patients drive everything we do. Our goal is to use
the latest science and technology and a patient-focused mindset to move away
from a one size fits all approach to more targeted and personalized
therapies,” Dr. Stoffels said. “This vision is aligned with Johnson &
Johnson’s mission to care for the world, one patient at a time. With broad
based expertise in healthcare R&D, we are uniquely positioned to lead the
development and application of personalized solutions for major disease
states.”

About the Personalized Medicine Coalition

The Personalized Medicine Coalition (PMC), representing a broad spectrum
of academic, industrial, patient, provider, and payer communities, seeks to
advance the understanding and adoption of personalized medicine concepts and
products for the benefit of patients. For more information on the Personalized
Medicine Coalition, please visit http://www.PersonalizedMedicineCoalition.org.

About the Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group
practice in the world. Doctors from every medical specialty work together to
care for patients, joined by common systems and a philosophy that “the needs
of the patient come first.” More than 3,300 physicians, scientists and
researchers and 41,000 allied health staff work at Mayo Clinic, which has
sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz.
Collectively, the three locations treat more than half a million patients each
year.

About Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
is a subsidiary of Johnson & Johnson, the world’s most broadly-based producer
of health care products. J&JPRD is headquartered in Raritan, N.J., and has
facilities throughout Europe, the United States and Asia. J&JPRD is
leveraging drug discovery and drug development in a variety of therapeutic
areas, including CNS, Pain, Cardiovascular, Metabolic, and Infectious
Diseases, to address unmet medical needs worldwide. More information can be
found at http://www.jnjpharmarnd.com.

     Contact:
     Elizabeth Schwinn, communications director, PMC
     (202) 589-1770
     eschwinn@personalizedmedicinecoalition.org

     Jane Jacobs, public affairs department, Mayo Clinic
     (507) 284-2387
     jacobs.jane@mayo.org

     Sri Ramaswami, senior director, global R&D communications, Johnson &
     Johnson Pharmaceutical Research and Development
     (609) 647-8195
     sramaswa@its.jnj.com

SOURCE Personalized Medicine Coalition


Source: newswire